IDEHU   05542
INSTITUTO DE ESTUDIOS DE LA INMUNIDAD HUMORAL PROF. RICARDO A. MARGNI
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Anti-tumoral effect of 4-methylumbelliferone on GL26 glioblastoma cell line.
Autor/es:
PIBUEL M.; HAJOS S. E.; MOLINARI Y.; LOMPARDÍA S. L.; DÍAZ M.; FRANCO P.
Lugar:
CABA
Reunión:
Congreso; 1st South American Glia Meeting; 2017
Resumen:
Glioblastoma is the most common and aggresive primary tumor of the central nervous system. This kind of tumor accumulates hyaluronic acid (HA), the main soluble glycosaminoglycan of the extracellular matrix. Treatment of glioblastoma cell lines with HA promotes cell proliferation, metabolic activity and induces cell migration, suggesting that HA would be involved in tumor progression. The cumarin-derived 4-methylumbelliferone (4MU) was shown to act as a potent inhibitor of HA synthesis. Although 4MU effects have been studied in several tumor types, its effects on glioblastoma cells has not been described yet.The aim of this work was to evaluate 4MU anti-tumoral activity on a mouse glioblastoma cell line (GL26) by analyzing how cell death, metabolic activity and migratory capacity were affected by in vitro treatment.A dose dependent reduction in cell viability after 48-72 h of 4MU treatment was shown. Cell metabolic activity was significantly reduced from 125 μM, reaching 70 % at 1000 μM. This result correlated with a dose and time-dependent increase in cell death. After 24 h of treatment 4MU inhibited cell migration in a dose-dependent manner. Cytotoxicity of 4MU was evaluated in primary cultures of normal neural cells. Results showed that cell viability in two different neural primary culture systems was mildly affected by 4MU as from 500 μM (20%). We conclude that 4MU exerts selective toxicity at 125 and 250 μM that affects viability and migration in GL26 cell line without affecting normal mouse brain cell cultures. Further studies must be done in order to clarify if this effect could be useful as an in vivo therapeutic approach for glioblastoma.